Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. carries a market capitalization of 2.31B, placing it among publicly traded companies globally. Its enterprise value stands at 2.78B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.31B |
| Enterprise Value | 2.78B |
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. currently has 534.07M shares outstanding.
| Shares Outstanding | 534.07M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. trades at a trailing price-to-earnings ratio of 48.66. The price-to-sales ratio is 1.70, and the price-to-book ratio stands at 2.61.
| PE Ratio | 48.66 |
| PS Ratio | 1.70 |
| PB Ratio | 2.61 |
| P/TBV Ratio | 1.57 |
| P/FCF Ratio | 66.88 |
| P/OCF Ratio | N/A |
On an enterprise value basis, Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. trades at an EV/EBITDA multiple of 20.60 and an EV/FCF ratio of 48.23. The EV/Sales ratio of 1.46 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 20.60 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.46 |
| EV / EBITDA | 20.60 |
| EV / EBIT | 20.60 |
| EV / FCF | 48.23 |
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. maintains a current ratio of 3.15, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 8.20, indicating elevated leverage, while an interest coverage ratio of 10.35 demonstrates strong ability to service its debt obligations.
| Current Ratio | 3.15 |
| Quick Ratio | 1.52 |
| Debt / Equity | 8.20 |
| Debt / EBITDA | 1.45 |
| Interest Coverage | 10.35 |
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. posts a return on equity of 5.32 and a return on invested capital of 3.82.
| Return on Equity (ROE) | 5.32 |
| Return on Assets (ROA) | 2.16 |
| Return on Invested Capital (ROIC) | 3.82 |
| Return on Capital Employed (ROCE) | 5.23 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 4.70 |
Over the trailing twelve months, Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. has paid 24.11M in income taxes, reflecting an effective tax rate of 28.13.
| Income Tax | 24.11M |
| Effective Tax Rate | 28.13 |
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd.'s stock has declined approximately -28.27381% over the past 52 weeks. The 50-day moving average sits at 5.24, while the 200-day moving average is 6.07.
| Beta (5Y) | N/A |
| 52-Week Price Change | -28.27381% |
| 50-Day Moving Average | 5.24 |
| 200-Day Moving Average | 6.07 |
| Average Volume (20 Days) | N/A |
Over the trailing twelve months, Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. generated 1.90B in revenue and converted that into 66.36M in net income, yielding earnings per share of 0.12. EBITDA reached 134.99M, while operating income came in at 134.99M.
| Revenue | 1.90B |
| Gross Profit | 897.65M |
| Operating Income | 134.99M |
| Pretax Income | 85.71M |
| Net Income | 66.36M |
| EBITDA | 134.99M |
| EBIT | 134.99M |
| Earnings Per Share (EPS) | 0.12 |
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. holds 721.53M in cash and equivalents against 195.86M in total debt, resulting in a net debt position of -532.79M. Total book value stands at 1.24B, with working capital of 1.02B providing operational flexibility.
| Cash & Cash Equivalents | 721.53M |
| Total Debt | 195.86M |
| Net Debt | -532.79M |
| Equity (Book Value) | 1.24B |
| Book Value Per Share | 2.48 |
| Working Capital | 1.02B |
After subtracting -48.28M in capital expenditures, free cash flow totaled -48.28M - equivalent to -0.10 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -48.28M |
| Free Cash Flow | -48.28M |
| FCF Per Share | -0.10 |
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. operates with a gross margin of 47.26, reflecting its pricing power and cost economics. The operating margin of 7.11 and net profit margin of 3.49 provide insight into operational efficiency.
| Gross Margin | 47.26 |
| Operating Margin | 7.11 |
| Pretax Margin | 4.51 |
| Profit Margin | 3.49 |
| EBITDA Margin | 7.11 |
The company's payout ratio of 162.57 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.18 |
| Dividend Yield | N/A |
| Payout Ratio | 162.57 |
| Shareholder Yield | 4.60 |
| FCF Yield | 1.50 |
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd.'s most recent stock split took place on July 6, 2015 with a 5:6 split ratio.
| Last Split Date | 7/6/2015 |
| Split Ratio | 5:6 |
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. posts an Altman Z-Score of 4.86, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.86 |